Prostate Cancer Risk in Relation to a Single Nucleotide Polymorphism in the Insulin-like Growth Factor-binding Protein-3 (IGFBP3) Gene: a Meta-analysis IGFBP3;prostate cancer;polymorphism;meta-analysis; Insulin-like growth factor-binding protein-3 (IGFBP3) has been identified as a putative tumor suppressor with multifunctional roles in the IGF axis. Recently, there have been a growing body of studies investigating the relation between the IGFBP3 A-202C polymorphism, circulating IGFBP3 and prostate cancer risk, but their outcomes varied leading to controversy. Hence, it is necessary to perform a meta-analysis covering all eligible studies to shed a light on the association of IGFBP3 A-202C and cancer risk. Finally, we included a total of 11 relevant articles between 2003 and 2010 covering 14 case-control studies including 9,238 cases and 8,741 controls for our analysis. Our results showed that A-202C was a marginal risk factor of prostate cancer (allele contrast: OR=1.08, 95% CI :1.01-1.16; dominant
Insulin-like growth factor binding protein-6 (IGFBP-6) is a growth inhibitory protein that regulates the availability of insulin-like growth factors (IGFs). We recently reported that IGFBP-6 exerts intracellular actions via its translocation to the nucleus. We now show that IGFBP-6 co-purifies by tandem-affinity with nuclear proteins involved in DNA stability and repair such as Ku80, Ku70, histone H2B and importin-alpha. Furthermore, this report shows that IGFBP-6 and Ku80 interact specifically using two active binding sites for Ku80 in IGFBP-6. One of the binding sites [196RKR199], as part of the NLS-sequence in IGFBP-6 also binds importin-alpha which may selectively compete with Ku80 regulating its trafficking to the nucleus. Moreover, IGFBP-6 co-localized with Ku80 based on a cell cycle pattern. Overexpression of IGFBP-6 increased the nuclear Ku80 in mitotic cells and reduced it post-mitosis. It is known that if highly expressed IGFBP-6 induces apoptosis and in our model, the down-regulation of Ku80
The insulin-like growth factors (IGFs), their receptors, and their binding proteins play key roles in regulating cell proliferation and apoptosis. Insulin-like growth factor binding protein-3 (IGFBP3, OMIM #146732) is one of the proteins that bind to the IGFs. IGFBP3 is a modulator of IGF bioactivity, and direct growth inhibitor in the extravascular tissue compartment. We identified twenty-two novel single nucleotide polymorphisms (SNPs) in IGFBP3 gene in Korean cattle (Hanwoo, Bos taurus coreanae) by direct sequencing of full gene including -1,500 bp promoter region. Among the identified SNPs, five common SNPs were screened in 650 Korean cattle; one SNP in promoter (IGFBP3 G-854C), one in 5`UTR region (IGFBP3 G-100A), two in intron 1 (IGFBP3 G+421T, IGFBP3 T+1636A), and one in intron 2 (IGFBP3 C+3863A). The frequencies of each SNP were 0.357 (IGFBP3 G-854C), 0.472 (IGFBP3 G-100A), 0.418 (IGFBP3 G+421T), 0.363 (IGFBP3 T+1636A) and 0.226 (IGFBP3 C+3863A), respectively. Haplotypes and their ...
The primary aim of this text is to gain insight on how cellular activation by a insulin-like growth factor (IGF-I), in the presence of insulin-like growth factor binding protein-3 (IGFBP-3), is influenced by heparan sulfate proteoglycans (HSPG). Initial research will be presented, assumptions and hypotheses that were included in the development of mathematical models will be discussed, and the future enhancements of the models will be explored. There are many potential scenarios for how each component might influence the others. Mathematical modeling techniques will highlight the contributions made by numerous extracellular parameters on IGF-I cell surface binding. Tentative assumptions can be applied to modeling techniques and predictions may aid in the direction of future experiments. Experimentally, it was found that IGFBP-3 inhibited IGF-I Bovine Aortic Endothelial (BAE) cell surface binding while p9 HS slightly increased IGF-I BAE cell surface binding. IGFBP-3 has a higher binding affinity ...
TY - JOUR. T1 - Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3. AU - Fielder, P. J.. AU - Rosenfeld, R. G.. AU - Graves, H. C.B.. AU - Grandbois, K.. AU - Maack, C. A.. AU - Sawamura, S.. AU - Ogawa, Y.. AU - Sommer, A.. AU - Cohen, P.. PY - 1994/12/1. Y1 - 1994/12/1. N2 - Prostate specific antigen (PSA) has been shown to proteolyze. IGFBP-3. However, the cleavage sites and mechanism of proteolysis are unknown. In this study, we proteolyzed recombinant human IGFBP-3 with PSA bound to a solid phase support. The reaction mixture was separated by centrifugation, with PSA remaining in the solid phase and the proteolyzed IGFBP-3 in the aqueous phase, The IGPBP-3 fragments were functionally analyzed by affinity labeling and Western ligand blotting (WLB). Further biochemical analyses were provided by silver staining of total protein and Western immunoblotting (WIB) of immunoreactive fragments with an IGFBP-3 specific antiserum (α-BP-3 gl). ...
TY - JOUR. T1 - Increased Proteolysis of Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) in Noninsulin-Dependent Diabetes Mellitus Serum, with Elevation of a 29-Kilodalton (kDa) Glycosylated IGFBP-3 Fragment Contained in the Approximately 130- To 150-kDa Ternary Complex. AU - Bang, Peter. AU - Brismar, Kerstin. AU - Rosenfeld, Ronald (Ron). PY - 1994/5. Y1 - 1994/5. N2 - Insulin-like growth factor-I (IGF-I) in serum is predominantly bound in a ternary complex, consisting of IGF peptide, IGF-binding protein-3 (IGFBP-3), and an acid-labile subunit, or a binary complex, consisting of IGF peptide and any of the six IGFBPs. In the binary complex, IGF-I is more bioavailable and has a faster turnover rate. Proteolysis of IGFBP-3 may alter the distribution of IGF-I between these complexes by reducing IGFBP-3 affinity for IGF-I and/or acid-labile subunit and may offer an additional mechanism for regulation of IGF availability. In the present study, sera from patients with noninsulin-dependent ...
AIM: To investigate the role of insulin-like growth factor binding protein-7 (IGFBP-7) in the activation and transdifferentiation of hepatic stellate cells (HSC) in vitro. METHODS: Rat HSC-T6 cells were cultured in separate dishes and treated with various concentration of transforming growth factor (TGF)-β1, IGFBP-7 or anti-IGFBP-7 antibody for 24 h. The supernatant or a cytoplasm suspension was obtained from cultured HSC, followed by transfer of cells to form cell-coated dishes. Immunocytochemistry and Western blotting were used to analyze the expression of IGFBP-7 induced by TGF-β1 and the level of fibronectin, collagen I and (α-smooth muscle actin (SMA). The pro-apoptotic effect of anti-IGFBP-7 antibody was determined by flow cytometry. RESULTS: Immunocytochemistry and Western blotting revealed that the expression of IGFBP-7 in TGF-β1 treated HSC was significantly up-regulated compared to that in the control group. In addition, fibronectin, collagen I and α-SMA also showed ...
Insulin-like growth factor binding proteins (IGFBPs) are known to be important modulators of the insulin-like growth factor (IGF-I). However, their precise role is as yet unclear. Further, recent studies have indicated that IGFBP-3 has a receptor mediated growth inhibitory response of its own. In the present study, we quantified the binding characteristics of IGFBP-3 to bovine aortic endothelial (BAE) cells. Binding studies at 4 oC were conducted and a specific binding curve for IGFBP-3 was obtained. IGFBP-3 was found to bind with an equilibrium dissociation constant (KD) value of 3.1 x 10-10 M. The role of heparan sulfate proteoglycans (HSPG) in the IGFBP-3 binding mechanism was also examined. It was seen that inactivation of the cell surface HSPGs with 75 mM sodium chlorate did not affect IGFBP-3 binding. Further, there have been reports of inhibition of IGFBP-3 binding by heparin in the media. Hence, the most probable interaction of HSPG with IGFBP-3 occurs in the extracellular region, with ...
We have previously demonstrated that insulin-like growth factor binding protein-5 (IGFBP-5) is upregulated following treatment of the mouse mammary epithelial cell line HC11 with lactogenic hormones (dexamethasone, insulin, and prolactin-DIP). In addition, we have also shown that IGFBP-5 is upregulated in mammary epithelial cells in vivo during involution of the rodent mammary gland. We have, therefore, postulated that there may be a dual regulation of IGFBP-5 expression during the temporally separated processes of differentiation and apoptosis of mammary epithelial cells. To test this hypothesis further, we have used a phenotypically differentiated model, which comprises primary cultures of mouse mammary epithelial cells grown on a layer of EHS (Engelbreth-Holm-Swarm) extracellular matrix. We show that lactogenic hormone treatment hydrocortisone, insulin, and prolactin-HIP) of these cultures induces the upregulation of IGFBP-5 thus replicating the results obtained with the HC11 cell line. In ...
Fisch, Thomas Martin (2005): Effects of insulin-like growth factor-binding protein-2 (IGFBP-2) overexpression on adrenal and renal growth processes and functions: findings in transgenic mouse models. Dissertation, LMU München: Tierärztliche Fakultät ...
Insulin-like growth factor-binding protein-2 and -3 in gingival crevicular fluid.: These results indicate that IGFBP-2 is a potential novel marker for periodont
In this analysis of women with BBD, we observed an inverse association between plasma IGF-1 and the IGF-1:IGFBP-3 ratio with predominant type 1/no type 3 lobules. Interestingly, only IGF-1 levels in the highest quartile were associated with a decreased odds of predominant type 1/no type 3 lobules, suggesting a potential threshold effect. However, we observed more of a linear trend for the IGF-1:IGFBP-3 ratio, which may better represent available IGF-1. The results did not materially change when we restricted our analysis to parous women or premenopausal women (Supplemental Tables 2 to 4 in Additional file 1).. Our findings are consistent with a study reporting that transgenic mice with IGF-1 overexpression in mammary tissue had inhibited postlactational involution [6]. In vivo studies in animals suggest that inhibition of postlactational involution increases the risk of subsequent mammary tumors [16]. In addition, recent studies in women have found that lobule type or degree of age-related ...
Background: Immunization against self-antigens can induce regulatory responses that inhibit the development of desirable Type I antitumor immune responses. Removing epitopes that bias toward a regulatory phenotype may enhance vaccine efficacy. We developed a novel IGFBP-2 targeting DNA plasmid vaccine capable of selectively inducing Type I immunity. IGFBP-2 is an important regulator of ovarian cancer invasiveness and metastases. Eradication of cancer cells expressing IGFBP-2 through effective immunization could prevent disease relapse or metastatic spread. Methods: In a single-arm non-randomized study of advanced stage (III/IV) or recurrent ovarian cancer patients treated to complete remission after primary or salvage therapy, 25 patients received 3 monthly doses of an IGFBP-2 DNA vaccine by intradermal injection. All adverse events (AE) were reported using the Common Terminology Criteria for Adverse Events Version 4.0. Overall survival (OS) was analyzed using the Kaplan-Meier method. ELISPOT ...
TY - JOUR. T1 - IGF-I/IGFBP-3 ratio. T2 - A mechanistic insight into the metabolic syndrome. AU - Sierra-Johnson, Justo. AU - Romero-Corral, Abel. AU - Somers, Virend K.. AU - Lopez-Jimenez, Francisco. AU - Mälarstig, Anders. AU - Brismar, Kerstin. AU - Hamsten, Anders. AU - Fisher, Rachel M.. AU - Hellénius, Mai Lis. PY - 2009/3/1. Y1 - 2009/3/1. N2 - Recent reports suggest that IGF (insulin-like growth factor)-I and IGFBP-3 (IGF-binding protein-3) have independent and opposing mechanistic effects on insulin. The aim of the present study was to assess the relationship between the IGF-I/IGFBP-3 ratio and the metabolic syndrome. We examined 3281 subjects (1463 men and 1818 women, aged 20-49 years), otherwise healthy adults, who participated in NHANES III (Third National Health and Nutrition Examination Survey), which has released measurements of IGF-I and IGFBP-3. Insulin resistance was estimated using the computer HOMA2 (homoeostatic model assessment 2) model. The updated ATP-III (Adult ...
Expression of IGF-binding protein-3 (IGFBP-3) and IGFBP-5 in human breast cancer cells induces apoptosis and is associated with modulations in Bcl-2 proteins, suggesting that these IGFBPs induce an intrinsic apoptotic pathway. In this study we demonstrate that although both IGFBPs induced the activation of caspase-8 and caspase-9, the expression of IGFBP-5, but not IGFBP-3, sensitized MDA-MB-231 breast cancer cells to the inhibitory effects of TNFalpha. This sensitivity to TNFalpha was associated with a block in nuclear factor-kappaB-mediated cell survival signals. IGFBP-5 expression was also associated with a caspase-8-independent activation of Bid, increased levels of cytosolic second mitochondria-derived activator of caspase (Smac)/direct inhibitor of apoptosis proteins (IAP) binding protein with low pI (DIABLO), and an enhanced phosphorylation of c-Jun N-terminal kinase, both basally and in response to TNFalpha. These results suggest that IGFBP-5 expression may influence extrinsic apoptotic pathways
Plasmid constructions. The IGFBP-3 sequences were excised from pSF202, pSF210, pSF211, and pSF207 containing the sequences for IGFBP-3 wild type, IGFBP-3KED253-255RGD, IGFBP-3 228KGRKR232NLS228MDGEA232, and IGFBP-3 Δ185-264, respectively ( 20) by NheI/HindIII and inserted into the cytomegalovirus (CMV) promoter-driven expression vector pX using SpeI/HindIII to generate pXIGFBP-3, pXIGFBP-3KED253-255RGD, and pXIGFBP-3 228KGRKR232NLS228MDGEA232. pXΔls-IGFBP-3 plasmids series: (a) To generate a new ATG start-site for the IGFBP-3 open reading frames without signal peptide (Δls), the oligonucleotide 5′-AATTCCATATGGGCGCGAGCTCGATATCA-3′ (MWG Biotech, Ebersberg, Germany) was inserted into the plasmid pUC19 digested with EcoRI and HindIII. The resulting plasmid is referred to pUC19-ATGnew. (b.1) To generate pXΔls-IGFBP-3, pXΔls-IGFBP-3KED253-255RGD, and pXΔls-IGFBP-3228KGRKR232NLS228MDGEA232, the plasmids pSF202, pSF210, and pSF211 were digested with HindIII and partially digested with SacI, ...
Insulin-like growth factor binding protein-5 (IGFBP-5) is an osteoblast secretory protein that becomes incorporated into the mineralized bone matrix. In osteoblast cultures, IGFBP-5 stimulates cell proliferation by an IGF-independent mechanism. To ev
Sigma-Aldrich offers abstracts and full-text articles by [Qiang You, Yan Wu, Nannan Yao, Guannan Shen, Ying Zhang, Liangguo Xu, Guiying Li, Cynthia Ju].
The main reason doctors order the IGF binding protein-3 (IGFBP3) test is to see if a person is producing a normal amount of human growth hormone.
1657 The effects of insulin-like growth factor binding protein-5 (IGFBP-5) on pancreatic cancer (PaC) cell lines transfected with vector (/Vec) or expressing a low (/BP5L) or high (/BP5H) level of IGFBP-5 showed that IGFBP-5 can inhibit (PANC-1) or enhance (MIA PaCa-2 and BxPC-3) cell growth. Cell cycle analysis revealed that in PANC-1 cells, IGFBP-5 induced G2/M cell cycle arrest independent of growth conditions. In MIA PaCa-2 cells, IGFBP-5 expression resulted in fewer cells in S phase compared to control cells (with or without serum) and an increase of cells in G2/M under normal growth conditions; whereas an increase of cells in G0/G1 was observed under serum-free conditions. In BxPC-3 cells grown with serum IGFBP-5 expression produced fewer cells in G0/G1 and an increase of cells in S phase. When grown without serum these effects were enhanced and lead to an increase of cells in G2/M. The PI3K and MAPK pathways were examined by western analysis to detect the activation status of Akt or ...
Objective Insulin-like growth factor-binding protein-2 (IGFBP-2) concentrations are low in subjects with metabolic syndrome and type 2 diabetes. Intriguingly, recent studies have demonstrated an association between high IGFBP-2 concentrations and increased mortality not only in populations with certain types of cancer, but also in relatively healthy populations. We evaluated the role of IGFBP-2 in relation to BMI and mortality. Design and Participants BMI, insulin sensitivity, insulin-like growth factor 1 (IGF-I) and IGFBP-2 were assessed repeatedly in 539 participants of the Baltimore Longitudinal Study of Aging around the ages of 55, 65 and 75 years. Results IGFBP-2 concentrations positively correlated with insulin sensitivity and inversely with BMI, both at baseline and follow-up. Independent of IGF-I, sex, BMI and insulin sensitivity, circulating IGFBP-2 levels positively correlated with age (P , 0.001). Changes over time in BMI were associated with an inverse correlation in IGFBP-2 ...
Insulin-like growth factor binding protein-6 (IGFBP-6), the main regulator of insulin-like growth factor-2 (IGF-2), is a component of the stem cell niche in developing muscle cells. However, its role in muscle development has not been clearly defined. In this study, we investigated the role of IGFBP-6 in muscle commitment and differentiation of human mesenchymal stem cells derived from the placenta. We showed that placental mesenchymal stem cells (PMSCs) have the ability to differentiate into muscle cells when exposed to a specific culture medium by expressing muscle markers Pax3/7, MyoD, myogenin, and myosin heavy chain in a stage-dependent manner with the ultimate formation of multinucleated fibers and losing pluripotency-associated markers, OCT4 and SOX2 ...
Low serum levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) are associated with Alzheimers Disease in men, but not women, according to a recent study accepted for publication ...
article{780ed7ed-740c-4d37-8ac0-560fc7767ebb, abstract = {BACKGROUND: As cardiovascular disease (CVD) is one of the most common causes of mortality worldwide, much interest has been focused on reliable methods to predict cardiovascular risk. DESIGN: A cross-sectional, population-based screening study with 17-year follow-up in Southern Sweden. METHODS: We compared a non-laboratory, consultation-based risk assessment method comprising age, sex, present smoking, prevalent diabetes or hypertension at baseline, blood pressure (systolic >/=140 or diastolic >/=90), waist/height ratio and family history of CVD to Systemic COronary Risk Evaluation (SCORE) and a third model including several laboratory analyses, respectively, in predicting CVD risk. The study included clinical baseline data on 689 participants aged 40-59 years without CVD. Blood samples were analyzed for blood glucose, serum lipids, insulin, insulin-like growth factor-I, insulin-like growth factor binding protein-1, C-reactive ...
Allander SV، Larsson C، Ehrenborg E، Suwanichkul A، Weber G، Morris SL، Bajalica S، Kiefer MC، Luthman H، Powell DR (May 1994). "Characterization of the chromosomal gene and promoter for human insulin-like growth factor binding protein-5". J Biol Chem. 269 (14): 10891-8. PMID 7511611. الوسيط ...
Proliferation of adipocyte precursors and their differentiation into mature adipocytes contributes to the development of obesity in mammals. IGF-I is a potent mitogen and important stimulus for adipocyte differentiation. The biological actions of IGFs are closely regulated by a family of IGF-binding proteins (IGFBPs), which exert predominantly inhibitory effects. IGFBP-2 is the principal binding protein secreted by differentiating white preadipocytes, suggesting a potential role in the development of obesity. We have generated transgenic mice overexpressing human IGFBP-2 under the control of its native promoter, and we show that overexpression of IGFBP-2 is associated with reduced susceptibility to obesity and improved insulin sensitivity. Whereas wild-type littermates developed glucose intolerance and increased blood pressure with aging, mice overexpressing IGFBP-2 were protected. Furthermore, when fed a high-fat/high-energy diet, IGFBP-2-overexpressing mice were resistant to the development of ...
Pampusch MS, Xi G, Kamanga-Sollo E, Loseth KJ, Hathaway MR, Dayton WR, White ME.J Endocrinol. 2005 Apr;185(1):197-206.Animal Growth and Development Laboratory, Department of Animal Science, University of Minnesota, St Paul, Minnesota 55108, USA.Abstr
Title of Dissertation: FUNCTION OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7(IGFBP7) IN HEPATOCELLULAR CARCINOMA By Dong Chen. Purpose: Hepatocellular carcinoma (HCC) is a highly virulent malignancy with no effective treatment, thus requiring the development of innovative and effective targeted therapies. The oncogene Astrocyte Elevated Gene-1 (AEG-1) plays a seminal role in hepatocarcinogenesis and profoundly downregulates Insulin-like Growth Factor Binding Protein-7 (IGFBP7). The present study focuses on analyzing potential tumor suppressor functions of IGFBP7 in HCC and the relevance of IGFBP7 downregulation in mediating AEG-1 function. Experimental Design: IGFBP7 expression was detected by immunohistochemistry in HCC tissue microarrays by real-time PCR and ELISA in human HCC cell lines. Dual Fluorescence in situ hybridization was performed to detect loss of heterozygosity at the IGFBP7 locus. Stable IGFBP7- overexpressing clones were established in the background of AEG-1- overexpressing human
Borai, A, Livingstone, C, Mehta, S, Zarif, H, Abdelaal, F and Ferns, G (2009) Biological variation in fasting serum insulin-like growth factor binding protein-1 (IGFBP-1) among individuals with a varying glucose tolerance ...
TY - JOUR. T1 - Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast. T2 - A cross-sectional study of women with benign breast disease. AU - Horne, Hisani N.. AU - Sherman, Mark E.. AU - Pfeiffer, Ruth M.. AU - Figueroa, Jonine D.. AU - Khodr, Zeina G.. AU - Falk, Roni T.. AU - Pollak, Michael. AU - Patel, Deesha A.. AU - Palakal, Maya M.. AU - Linville, Laura. AU - Papathomas, Daphne. AU - Geller, Berta. AU - Vacek, Pamela M.. AU - Weaver, Donald L.. AU - Chicoine, Rachael. AU - Shepherd, John. AU - Mahmoudzadeh, Amir Pasha. AU - Wang, Jeff. AU - Fan, Bo. AU - Malkov, Serghei. AU - Herschorn, Sally. AU - Hewitt, Stephen M.. AU - Brinton, Louise A.. AU - Gierach, Gretchen L.. PY - 2016/2/18. Y1 - 2016/2/18. N2 - Background: Terminal duct lobular units (TDLUs) are the primary structures from which breast cancers and their precursors arise. Decreased age-related TDLU involution and elevated mammographic ...
Expression of insulin-like growth factor binding protein 5 (IGFBP5) is strongly induced upon activation of hepatic stellate cells and their transdifferentiation into myofibroblasts in vitro. This was confirmed in vivo in an animal model of liver fibrosis. Since IGFBP5 has been shown to promote fibrosis in other tissues, the aim of this study was to investigate its role in the progression of liver fibrosis. The effect of IGFBP5 was studied in LX2 cells, a model for partially activated hepatic stellate cells, and in human primary liver myofibroblasts. IGFBP5 signalling was modulated by the addition of recombinant protein, by lentiviral overexpression, and by siRNA mediated silencing. Furthermore, the addition of IGF1 and silencing of the IGF1R was used to investigate the role of the IGF-axis in IGFBP5 mediated effects. IGFBP5 enhanced the survival of LX2 cells and myofibroblasts via a |50% suppression of apoptosis. This effect of IGFBP5 was not modulated by the addition of IGF1, nor by silencing of the
We have investigated the expression and secretion of insulin-like growth factor binding proteins (IGFBPs-1 to -6) in human vascular smooth muscle cells (hVSMCs) cultured from human renal arteries. Solution hybridization was used to determine IGFBP nRNA levels and Western immunoblot to detect the corresponding peptides. The hVSMCs expressed mRNAs for IGFBPs-2 to -6, IGFBP-1 mRNA was not detected. IGFBPs-3, -4 and -6 mRNAs were the most abundant, IGFBP-5 was also highly expressed, whereas the IGFBP-2 mRNA was just above the limit of detection. Serum starvation for 48 h significantly decreased the mRNA levels of IGFBPs-2 to -5 and tended to decrease IGFBP-6 mRNA also. IGFBPs-2, -4, -5 and -6 peptides could be detected in conditioned medium, but IGFBP-3 peptide was not detected. IGFBP-4 was the only peptide detected without any concentration step. Low-molecular-mass immunoreactive degradation products were found for IGFBPs-2 and -4. Exogenous IGFBPs-1, -3 and -4 in concentrations of 50 ng/ml ...
Vascular function is greatly influenced by growth factors and regulatory molecules that can interact with each other in a complex pattern in the vascular wall. In this thesis we studied how different substances of special interest in the pathogenesis of vascular disease interact and regulate each others expressions in endothelial cells and vascular smooth muscle cells (VSMCs).. In VSMCs, angiotensin II was shown to delay PDGF-BB induced cell growth. This transient inhibitory effect of angiotensin II was mediated by the AT1-receptor, did not involve autocrine action of transforming growth factor-ß1 (TGF-ß1) and acted at a site downstream of PDGF-ß receptor phosphorylation.. The interaction of the insulin-like growth factor-system (IGF-system) with various growth factors, glucose and nitric oxide (NO) was studied in vascular cells. Vascular endothelial growth factor (VEGF) and transforming growth factor-ß1 (TGF-ß1) regulated the expression of insulin-like growth factor-binding proteins ...
Insulin-like growth factor (IGF)-I and its main binding protein, IGFBP-3, modulate cell growth and survival,and thus are thought to be important for tumor development. Carotenoids and retinol have been linked to theprevention of several cancers. We here evaluated associations of serum levels of carotenoids and retinol withIGF-I, IGF-II, and IGFBP-3 within the context of the JACC Study. The study subjects were 924 controls (578men and 346 women) of a nested case-control study of lung and colorectal cancer risk . Using frozen-stored sera,serum levels of α-carotene, β-carotene, lycopene, β-cryptoxanthin, zeaxanthin/lutein, and retinol were separatelydetermined using high-performance liquid chromatography. Serum levels of IGF-I, IGF-II, and IGFBP-3 weremeasured by immuno-radiometric assay. Confounding factors-adjusted least squares mean levels of serum IGFI,IGF-II, and IGFBP-3 for each quartile of serum levels of carotenoids and retinol were estimated. Serum IGFI,IGF-II, and IGFBP-3 levels increased with
The associations between serum concentrations of insulin-like growth factor-I (IGF-I), IGF-II and IGF-binding proteins (IGFBP)-3 and risk of breast cancer were investigated in a nested case-control study involving 117 cases (70 premenopausal and 47 postmenopausal at blood collection) and 350 matched controls within a cohort of women from the island of Guernsey, UK. Women using exogenous hormones at the time of blood collection were excluded. Premenopausal women in the top vs bottom third of serum IGF-I concentration had a nonsignificantly increased risk for breast cancer after adjustment for IGFBP-3 (odds ratio (OR) 1.71; 95% confidence interval (CI): 0.74-3.95; test for linear trend, P=0.21). Serum IGFBP-3 was associated with a reduction in risk in premenopausal women after adjustment for IGF-I (top third vs the bottom third: OR 0.49; 95% CI: 0.21-1.12, P for trend=0.07). Neither IGF-I nor IGFBP-3 was associated with risk in postmenopausal women and serum IGF-II concentration was not associated with
Reactivity: Chicken, Human, Monkey and more. Compare 11 different IGFALS ELISA Kits & buy the right one directly at antibodies-online.com!
Reaktivität: Huhn, Human, Affe and more. 16 verschiedene IGFALS ELISA Kits vergleichen. Alle direkt auf antikoerper-online.de bestellbar!
Zhou, X.; Hintz, R. L.; LIN, Ting Kwong; How, W. H. K.; Aw, T C; and Lee, K O. Serum Insulin-Like Growth Factor-I (Igf-I) and Dehydroepiandrosterone-Sulphate (Dhea-S) in a Community Dwelling Elderly Population. (1997). Endocrinology and Metabolism. 4, (5), 345-351. Research Collection School Of Economics ...
Introduction: In this study, we compared human placental gene expression patterns of IGF from pregnancies that ended with preterm delivery versus full term pregnancies as controls. We also assessed differences in clinical characteristics in the two groups. Materials and Methods: We used real-time PCR to assess gene expression patterns of IGF in human placental samples from 104 preterm and 140 full term pregnancies (control group) at the time of delivery. Clinical data were collected from our computerized database. Results: Pre-gestational Body Mass Index (BMI) was not significantly different in the two groups. In the preterm delivery group, the proportion of smokers was 26.9%, significantly higher than in the control group (7.1%, p,0.05). Preterm delivery began with premature rupture of membranes in 70.2% and spontaneous uterine activity in 29.8%. History of preterm delivery was present in 14.4% in the preterm delivery group compared to only 4.3% of the control group (p,0.05). In preterm ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
The present study establishes the cellular sites of expression of several components of the IGF system in adult rat liver, a predominant source of circulating IGF-I in adult rat and other mammals (17, 19). As expected, IGF-I mRNA was highly expressed in hepatocytes. IGF-I mRNAs were also demonstrated in Kupffer cells and hepatic endothelial cells. These findings indicate that IGF-I secreted from nonparenchymal cells may contribute to the circulating pool of IGF-I derived from liver, albeit at lower levels than IGF-I derived from hepatocytes. Kupffer and endothelial cells play a key role in immune recognition, cytokine production, and immune cell recruitment within the liver (11). In other systems, IGF-I expression by macrophages and endothelial cells may participate in processes such as wound healing (28) and vascular repair after endothelial damage (43) and in the pathogenesis of pulmonary and intestinal fibrosis (29, 51). Our present findings raise the possibility that IGF-I derived from ...
The views presented here are those of the author and are not to be construed as official or reflecting the views of the Uniformed Services University of the Health Sciences, the Department of Defense or the U.S. Government ...
Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an IGFBP7 agent if t
Background Insulin-like growth factor I (IGF-I), which is mostly carried in blood by IGF-binding protein 3 (IGFBP-3), was associated to the glomerular filtration rate and chronic kidney disease in a...
Reaktivität: Huhn, Rind (Kuh), Hund and more. 110 verschiedene IGFBPI ELISA Kits vergleichen. Alle direkt auf antikoerper-online.de bestellbar!
We hypothesized that ratios of pro- to anti-inflammatory cytokines can be associated with hepatic, cardiac, and renal function after a severe trauma and can be used as predictors for clinical outcome. Furthermore, insulin-like growth factor-I (IGF-I) in combination with its principle binding protein (IGFBP-3) equilibrates proto anti-inflammatory cytokine ratios and improves homeostasis of severely burned pediatric patients. Seventeen severely burned children were given a continuous infusion of IGF-I/BP-3 for 5 days after wound excision and grafting; seven were given saline during the same time period to serve as controls. Patient demographics and mortality were determined. Five days after excision and grafting, cardiac function was determined and blood samples were taken for serum levels of IGF-I, IGFBP-3, creatinine, pre-albumin, cholinesterase, pro-inflammatory cytokines (IL-1β, IL-6, and TNF), and anti-inflammatory cytokines (IL-2, IL-4, IL-10 and IFN-γ). There were no differences between IGF-I/BP
In vitro studies have shown that insulin-like growth factor (IGF) is a mitogen for breast cancer cells. However, the associations of plasma IGF-I with tumor histopathology in high-risk groups need fur
OBJECTIVE: To determine whether perturbations of insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) were associated with the presence of chronic widespread pain (CWP) in men. METHODS: The European Male Ageing Study (EMAS) is an 8-center population-based study of men aged 40-79 years recruited from population registers. A questionnaire asked about the presence and duration of musculoskeletal pain, from which subjects reporting CWP were identified. Subjects also had an interviewer-assisted questionnaire: levels of physical activity and mood were assessed, and height and weight were measured. IGF-1 and IGFBP-3 were assayed from a fasting blood sample. Logistic regression models were used to determine the association between IGF measures and CWP. Results were expressed as odds ratios or relative risk ratios. RESULTS: A total of 3206 subjects provided full data. Of those, 1314 (39.0%) reported no pain in the past month and 278 (8.3%) reported pain that satisfied criteria for CWP. IGF-1
Increasing of body weight has been one of the important economic factors in the poultry industry. Insulin-like growth factor (IGF)-I is a polypeptide that serves to regulate muscle development and body growth. Moreover, IGF-I is related to feed efficiency. However, there are few studies regarding the regulatory roles of chicken IGF-I/-II compared with that of mammals. Especially, the Korean Native Ogol Chicken (KNOC) has a lean body growth and its body weight is generally lighter than the broiler chicken. Therefore, this study was conducted to investigate associations among serum IGF-I/-II concentration, feed efficiency, and body growth in KNOC. The body weight and feed intake of KNOC were recorded from 20 to 36 weeks at 2 weeks intervals, and blood was taken every 2 weeks. Serum IGF-I/-II were measured by RIA. Chickens were divided into two groups, high and low serum IGF-I concentration. Generally, feed efficiency and growth performance (body weight and weight gain) in the high serum IGF-I ...